Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1957 2
1958 1
1959 2
1962 1
1964 1
1968 1
1969 4
1970 4
1971 2
1972 2
1973 3
1974 2
1975 5
1976 7
1977 4
1978 2
1979 6
1980 6
1981 8
1982 11
1983 6
1984 13
1985 4
1986 1
1987 3
1988 5
1989 2
1990 2
1991 4
1992 6
1993 4
1994 1
1995 2
1996 4
1997 7
1998 5
1999 1
2000 5
2001 2
2002 3
2003 5
2004 3
2005 9
2006 8
2007 16
2008 11
2009 13
2010 17
2011 18
2012 18
2013 30
2014 20
2015 38
2016 41
2017 43
2018 41
2019 35
2020 33
2021 14
Text availability
Article attribute
Article type
Publication date

Search Results

509 results
Results by year
Filters applied: . Clear all
Page 1
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E Jr, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV. Kumar SK, et al. Among authors: parsons b. Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28. Lancet Oncol. 2020. PMID: 32866432 Clinical Trial.
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M, Xu-Monette ZY, Pham LV, Wang X, Tzankov A, Fang X, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Hagemeister F, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Liu P, Young KH. Deng M, et al. Among authors: parsons bm. Mol Cancer Res. 2021 Feb;19(2):249-260. doi: 10.1158/1541-7786.MCR-20-0466. Epub 2020 Nov 5. Mol Cancer Res. 2021. PMID: 33154093
Skin-interfaced biosensors for advanced wireless physiological monitoring in neonatal and pediatric intensive-care units.
Chung HU, Rwei AY, Hourlier-Fargette A, Xu S, Lee K, Dunne EC, Xie Z, Liu C, Carlini A, Kim DH, Ryu D, Kulikova E, Cao J, Odland IC, Fields KB, Hopkins B, Banks A, Ogle C, Grande D, Park JB, Kim J, Irie M, Jang H, Lee J, Park Y, Kim J, Jo HH, Hahm H, Avila R, Xu Y, Namkoong M, Kwak JW, Suen E, Paulus MA, Kim RJ, Parsons BV, Human KA, Kim SS, Patel M, Reuther W, Kim HS, Lee SH, Leedle JD, Yun Y, Rigali S, Son T, Jung I, Arafa H, Soundararajan VR, Ollech A, Shukla A, Bradley A, Schau M, Rand CM, Marsillio LE, Harris ZL, Huang Y, Hamvas A, Paller AS, Weese-Mayer DE, Lee JY, Rogers JA. Chung HU, et al. Among authors: parsons bv. Nat Med. 2020 Mar;26(3):418-429. doi: 10.1038/s41591-020-0792-9. Epub 2020 Mar 11. Nat Med. 2020. PMID: 32161411 Free PMC article.
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL.
Xu-Monette ZY, Zhang H, Zhu F, Tzankov A, Bhagat G, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Hagemeister FB, Shahbaba B, De Dios I, Zhang H, Li Y, Xu B, Albitar M, Young KH. Xu-Monette ZY, et al. Among authors: parsons bm. Blood Adv. 2020 Jul 28;4(14):3391-3404. doi: 10.1182/bloodadvances.2020001949. Blood Adv. 2020. PMID: 32722783 Free PMC article.
Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use.
Parsons BN, Ijaz UZ, D'Amore R, Burkitt MD, Eccles R, Lenzi L, Duckworth CA, Moore AR, Tiszlavicz L, Varro A, Hall N, Pritchard DM. Parsons BN, et al. PLoS Pathog. 2017 Nov 2;13(11):e1006653. doi: 10.1371/journal.ppat.1006653. eCollection 2017 Nov. PLoS Pathog. 2017. PMID: 29095917 Free PMC article.
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.
Deng M, Zhang M, Xu-Monette ZY, Pham LV, Tzankov A, Visco C, Fang X, Bhagat G, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Choi WWL, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Hagemeister F, Alinari L, Li Y, Andreeff M, Xu B, Young KH. Deng M, et al. Among authors: parsons bm. J Hematol Oncol. 2020 Nov 4;13(1):148. doi: 10.1186/s13045-020-00982-3. J Hematol Oncol. 2020. PMID: 33148342 Free PMC article.
509 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page